Gov Influence
Menu

Organization profile

Pfizer

Pfizer's profile follows reviewed federal filings centered on health, prescription drugs, Medicare and Medicaid, tax, trade, tariffs, labor, budget, and intellectual property. It was selected as a focused pharmaceutical-policy example with a smaller filing set and identifiable outside-firm relationships. Health Issues supplies the strongest recurring pattern across the current quarters, while the detailed records preserve the specific bills and policy topics reported by filers.

Data retrieved through Sep 4, 2026; profile content reviewed Sep 6, 2026

Editorial illustration for the Pfizer profile.

Gov Influence analytical brief

Bottom-line assessment

Gov Influence assessmentModerate confidence

Health Issues was a sustained component of Pfizer’s reported federal policy activity in the reviewed period.

HCR appeared in 6 retained filings across both quarters; the full profile spans 9 official issue codes and 8 filings.

Evidence and reasoning

Reasoning: The same official issue code appears in independently filed records in both comparable quarters, so the pattern is broader than a one-time reference. Its recurrence, read alongside the profile’s filing and issue coverage, supports a bounded assessment of sustained attention—not a conclusion about policy position, priority, access, effectiveness, or influence.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Pfizer.

Other plausible interpretation

  • The recurrence may partly reflect the breadth of the official HCR category and the selected two-quarter window; it does not establish a longer-term trend or show that this subject outranked every other concern.

Method: organization-profile-assessment-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

A policy or bill named in a filing documents reported subject matter, not Pfizer's position, contact with a particular official, or effect on an outcome.

Why this matters

What the pattern adds to the record

Health Issues is the recurring center of the current filing set, with pharmacy, Medicare and Medicaid, trade, tax, and intellectual-property records supplying the surrounding policy context.

Supporting analysis

Key findings

Calculated from recordsHigh confidence

Pfizer’s organization-expense and outside-firm-income fields are compared separately.

Organization-reported expenses decreased by $2,540,000; outside-firm-reported income was unchanged.

Evidence and reasoning

Reasoning: The comparison evaluates the same measure across Q1 and Q2 only when both quarters have complete numeric inputs. Organization-reported expenses and outside-firm income use different reporting bases, so they remain separate; partial, below-threshold, absent, and non-applicable values are never converted to zero or combined.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Pfizer.

Method: organization-amount-comparison-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

Pfizer’s reviewed filings span 9 official issue codes.

The highest filing frequency is 6, for HCR; codes can overlap within a filing and measure subject breadth rather than importance.

Evidence and reasoning

Reasoning: The calculation counts each official LDA issue code once per retained filing, allows different codes to overlap, and uses deterministic code-order tie handling. Breadth and frequency describe how source records are categorized; they do not reveal position, intensity, or success.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Pfizer.

Method: organization-issue-breadth-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

3 reviewed outside-firm relationships are visible in Pfizer’s retained filings.

6 retained filings identify one of those approved firm registrant IDs and a client name admitted by Pfizer’s exact-name rule.

Evidence and reasoning

Reasoning: Each relationship requires both a reviewed registrant identity and an organization client name admitted by the exact-name rule in the same canonical filing. The count maps disclosed firm-client structure only; it does not establish access, coordination, effectiveness, or activity outside this collection.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Pfizer.

Method: organization-firm-relationships-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Show 1 additional reviewed finding
Calculated from recordsHigh confidence

Pfizer has the same retained filing count in both reviewed quarters.

8 canonical filings are included: 4 in 2026 Q1 and 4 in 2026 Q2.

Evidence and reasoning

Reasoning: This count groups canonical filings by their reported quarter after the reviewed exact-alias and amendment-selection rules. The comparison measures retained filing frequency in this collection, not effort, spending, access, effectiveness, or policy impact.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Pfizer.

Method: quarter-filing-count-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Focused starting collection

Why this is in the initial collection

Pfizer adds a concentrated health-policy perspective to a collection that also includes technology, aerospace, retail, and membership organizations. Its filings make it possible to compare a recurring health category with narrower pharmacy, Medicare, tax, trade, and intellectual-property subjects. The profile also shows how named bills can remain useful source language without being converted automatically into claims about the company's position or an effect on legislation.

What this edition covers: The page compares retained Q1 and Q2 2026 filings for the reviewed Pfizer Inc. identity and keeps each outside-firm income field separate from other reporting bases.

Questions this page helps answer

  • Which health-policy subjects recur?
  • How do pharmacy and Medicare records relate to the broader health category?
  • What do named bills in filing text establish?
Site calculation

Retained filings by quarter

The two bars compare filing counts within the 2026 Q1 through 2026 Q2 reviewed collection. Exact counts and each quarter's share of all 8 retained filings appear in the table.

Exact filing-count comparison
QuarterRetained filingsShare of period total
2026 Q1450% of 8
2026 Q2450% of 8

Filing counts show how many records are in this collection. They do not measure effort, importance, access, or results.

Context, not causation

Why these records are connected

Issue pages are connected through reviewed filing codes. Other categories appear only when a separate identity or subject link passed review.

Context onlyReviewed issue grouping

Healthcare, Prescription Drugs and Medicare

Why connected: 8 of 8 retained filings from 2026 Q1 through 2026 Q2 carry at least one of this issue page's reviewed codes (HCR, MMM, PHA).

This code match explains the pathway. It does not show a position, coordinated activity, political importance, or an effect on policy.

Context onlyReviewed issue grouping

Taxes and Government Spending

Why connected: 5 of 8 retained filings from 2026 Q1 through 2026 Q2 carry at least one of this issue page's reviewed codes (BUD, TAX).

This code match explains the pathway. It does not show a position, coordinated activity, political importance, or an effect on policy.

Identified in retained LDA filings

Outside firms in these reviewed filings

Each firm below is linked because retained filings identify both this organization's reviewed client name and the firm's reviewed LDA registrant ID. The relationship does not establish access, effectiveness, coordination, or policy impact.

Outside lobbying firm

Miller Strategies, LLC

Filing basis: 2 retained canonical LDA filings identify registrant ID 401104313 and a client name admitted by Pfizer's reviewed exact-name rule. The records span 2026-Q1 and 2026-Q2.

Inspect the 2 supporting filings
Explore this firm's reviewed clients and filings

Outside lobbying firm

The Duberstein Group Inc.

Filing basis: 2 retained canonical LDA filings identify registrant ID 12675 and a client name admitted by Pfizer's reviewed exact-name rule. The records span 2026-Q1 and 2026-Q2.

Inspect the 2 supporting filings
Explore this firm's reviewed clients and filings

Outside lobbying firm

Todd Strategy Group

Filing basis: 2 retained canonical LDA filings identify registrant ID 401103321 and a client name admitted by Pfizer's reviewed exact-name rule. The records span 2026-Q1 and 2026-Q2.

Inspect the 2 supporting filings
Explore this firm's reviewed clients and filings
Lobbying disclosure

Detailed lobbying records

The summaries above come from these records. A disclosure reports activity under federal law; it does not show that the activity achieved a policy result.

Quarterly amounts, kept separate

Self-reported expenses and income reported by outside firms have different reporting bases. They appear in separate tables and are never added into one total.

Organization self-reported expense fields
Reporting quarterMeasureValue or stateInput states
2026 Q1Self-reported expenses$4,420,0004 filings; 1 numeric; 3 other-measure; 0 unavailable
2026 Q2Self-reported expenses$1,880,0004 filings; 1 numeric; 3 other-measure; 0 unavailable

For each quarter, sum only retained filings' self-reported expense fields. A blank expense field is excluded from this series when the same filing establishes an outside-income reporting basis. Keep zero and every unavailable state visible; never add outside-registrant income. Reviewed 2026-09-04.

Outside-firm income fields
Reporting quarterMeasureValue or stateInput states
2026 Q1Outside-registrant income$270,0004 filings; 3 numeric; 1 other-measure; 0 unavailable
2026 Q2Outside-registrant income$270,0004 filings; 3 numeric; 1 other-measure; 0 unavailable

For each quarter, sum only retained filings' outside-registrant income fields. A blank income field is excluded from this series when the same filing establishes a self-expense reporting basis. Keep zero and every unavailable state visible; never add self-reported expenses. Reviewed 2026-09-04.

Lobbying filings used for coverage and amount calculations

Show 3 more source records

Issue categories and source wording

Health Issues, Pharmacy, Medicare/Medicaid, Taxation, Trade, Tariff, Labor, Budget, and intellectual-property codes remain separate in the table. The site does not collapse them into a single health-policy label.

Open the full issue-code table and wording checks
Site calculation

Official issue-code distribution

Count every official LDA issue code present in the retained canonical filings. Count a filing once per code, preserve the official source label, and identify a normalized directory group only when the code is in that group's reviewed allowlist.

Codes in the retained canonical filings; counts may overlap
Code and official labelFilingsActivitiesNormalized directory group
BUD — Budget/Appropriations22taxes government spending
CPT — Copyright/Patent/Trademark22No current directory group
HCR — Health Issues66healthcare drug policy medicare
LBR — Labor Issues/Antitrust/Workplace22No current directory group
MMM — Medicare/Medicaid44healthcare drug policy medicare
PHA — Pharmacy22healthcare drug policy medicare
TAR — Tariff (miscellaneous tariff bills)22No current directory group
TAX — Taxation/Internal Revenue Code33taxes government spending
TRD — Trade (domestic/foreign)44No current directory group

Reviewed 2026-09-04.

Explicit language check

Technology-code filings (CPI, SCI, or TEC)
0
Filings explicitly saying AI or artificial intelligence
0
Filings explicitly using reviewed privacy terms
0
Technology-code filings without either explicit match
0

Search retained source descriptions case-insensitively for the exact phrase 'artificial intelligence' or the standalone abbreviation 'AI', and for 'privacy', 'personal data', or 'data protection'. Separately count filings carrying CPI, SCI, or TEC codes.

This literal-language check distinguishes explicit source wording from broad LDA categories. It does not infer that other technology-coded descriptions concern AI or privacy, and it does not classify a position on any issue.

Read representative filing language

Representative source language

Use canonical filings only; group exact source descriptions by reviewed issue code, sort codes and filings deterministically, select one description per code before selecting a second from any code, and preserve the source text exactly.

Issues related to FY27 health appropriations

BUD: Budget/Appropriations; 2026 Q1; reviewed 2026-09-04View original filing

Oppose IRA, PREP Act and vaccine liability.

HCR: Health Issues; 2026 Q1; reviewed 2026-09-04View original filing

Medicare and healthcare policy issues as they relate to drug pricing.

MMM: Medicare/Medicaid; 2026 Q1; reviewed 2026-09-04View original filing

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.

PHA: Pharmacy; 2026 Q1; reviewed 2026-09-04View original filing

General issues with tax reform and foreign tax issues.

TAX: Taxation/Internal Revenue Code; 2026 Q1; reviewed 2026-09-04View original filing
Review outside-firm filing counts

Outside registrant context

Treat a registrant as outside-firm context only when the retained filing establishes the outside-registrant income reporting basis. Group the exact registrant name by reporting quarter without resolving firms beyond the reviewed filing identity.

Exact registrant organization names and retained filing counts
Registrant2026-Q12026-Q2Period total
MILLER STRATEGIES, LLC112
THE DUBERSTEIN GROUP INC.112
TODD STRATEGY GROUP112

These are registrant organizations named on retained filings, not individual lobbyists. A filing count does not measure effort, access, effectiveness, or policy result.

Retained filing records

Records are grouped by reporting quarter. Each disclosure opens with a keyboard-accessible summary and preserves its official code, description, amount states, and direct source.

2026-Q14 filings
PFIZER INC.1st Quarter (Jan 1 - Mar 31), 2026
Client name in filing
PFIZER INC.
Reported income
Unreported
Reported expenses
$4,420,000

CPT — Copyright/Patent/Trademark

Intellectual Property Protections

Government entities listed: HOUSE OF REPRESENTATIVES

HCR — Health Issues

Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025

Government entities listed: Executive Office of the President (EOP), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

MMM — Medicare/Medicaid

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues

Government entities listed: Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

TRD — Trade (domestic/foreign)

International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues

Government entities listed: Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

MILLER STRATEGIES, LLC1st Quarter (Jan 1 - Mar 31), 2026
Client name in filing
PFIZER INC.
Reported income
$150,000
Reported expenses
Unreported

MMM — Medicare/Medicaid

Medicare and healthcare policy issues as they relate to drug pricing.

Government entities listed: HOUSE OF REPRESENTATIVES, Treasury, Dept of

HCR — Health Issues

Oppose IRA, PREP Act and vaccine liability.

TAX — Taxation/Internal Revenue Code

General issues with tax reform and foreign tax issues.

LBR — Labor Issues/Antitrust/Workplace

Issues related to drug consolidation.

THE DUBERSTEIN GROUP INC.1st Quarter (Jan 1 - Mar 31), 2026
Client name in filing
PFIZER INC.
Reported income
$60,000
Reported expenses
Unreported

BUD — Budget/Appropriations

Issues related to FY27 health appropriations

Government entities listed: HOUSE OF REPRESENTATIVES, SENATE

HCR — Health Issues

Issues related to 340B Program Issues related to drug pricing

Government entities listed: HOUSE OF REPRESENTATIVES, White House Office

TODD STRATEGY GROUP1st Quarter (Jan 1 - Mar 31), 2026
Client name in filing
PFIZER INC.
Reported income
$60,000
Reported expenses
Unreported

PHA — Pharmacy

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

TAR — Tariff (miscellaneous tariff bills)

Issues related to tariff and trade policy. International Supply Chain.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

TRD — Trade (domestic/foreign)

Issues related to tariff and trade policy.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

2026-Q24 filings
THE DUBERSTEIN GROUP INC.2nd Quarter (Apr 1 - June 30), 2026
Client name in filing
PFIZER INC.
Reported income
$60,000
Reported expenses
Unreported

BUD — Budget/Appropriations

Issues related to FY27 health appropriations

Government entities listed: HOUSE OF REPRESENTATIVES, SENATE

HCR — Health Issues

Issues related to 340B Program Issues related to drug pricing

Government entities listed: HOUSE OF REPRESENTATIVES, White House Office

PFIZER INC.2nd Quarter (Apr 1 - June 30), 2026
Client name in filing
PFIZER INC.
Reported income
Unreported
Reported expenses
$1,880,000

CPT — Copyright/Patent/Trademark

Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act

Government entities listed: SENATE

HCR — Health Issues

Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage

Government entities listed: HOUSE OF REPRESENTATIVES, SENATE

MMM — Medicare/Medicaid

H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues

Government entities listed: HOUSE OF REPRESENTATIVES, SENATE

TAX — Taxation/Internal Revenue Code

H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14

Government entities listed: HOUSE OF REPRESENTATIVES

TRD — Trade (domestic/foreign)

H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues

Government entities listed: Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

MILLER STRATEGIES, LLC2nd Quarter (Apr 1 - June 30), 2026
Client name in filing
PFIZER INC.
Reported income
$150,000
Reported expenses
Unreported

MMM — Medicare/Medicaid

Medicare and healthcare policy issues as they relate to drug pricing.

HCR — Health Issues

Issues related to 340B Program

Government entities listed: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

TAX — Taxation/Internal Revenue Code

General issues with tax reform and foreign tax issues.

LBR — Labor Issues/Antitrust/Workplace

Issues related to drug consolidation.

Government entities listed: Federal Trade Commission (FTC)

TODD STRATEGY GROUP2nd Quarter (Apr 1 - June 30), 2026
Client name in filing
PFIZER INC.
Reported income
$60,000
Reported expenses
Unreported

PHA — Pharmacy

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

TAR — Tariff (miscellaneous tariff bills)

Issues related to tariff and trade policy. International Supply Chain.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

TRD — Trade (domestic/foreign)

Issues related to tariff and trade policy.

Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE

Legislative record

Separate legislative context

No approved record in this collection

What was checked: Congress.gov records and the curated entity-link registry for this organization

What this means: No legislative context has passed review for this page. This does not mean no relevant legislation or filing references exist.

Political-finance record

Separate political-finance context

No approved record in this collection

What was checked: FEC committee records and the curated identity-link registry for this organization

What this means: No organization-linked committee aggregate has passed identity review for this page. This does not mean no committee relationship exists.

Federal award

Separate federal-award context

No approved record in this collection

What was checked: USAspending records and the curated recipient-identity link registry for this organization

What this means: No federal-award record has passed recipient-identity review for this page. This does not mean no award exists.

Methods and full limitations

How this page was prepared

This profile includes only the exact reviewed Pfizer Inc. client alias; punctuation variants returned by the search remain outside the retained set.

Review identity, coverage, and calculation details
Public display name
Pfizer
Canonical source name
Pfizer Inc.
Organization type
Corporation
Profile reporting period
Q1–Q2 2026

No former-name evidence is used for this profile.

Site calculation

Coverage summary

Count canonical filings after the reviewed exact-alias and amendment/duplicate rules; group each retained filing by its reported year and quarter.

Period
2026 Q1 through 2026 Q2
Canonical filings
8
Source-record client names
1
Registrant names
4
Retained filing counts by reporting quarter
QuarterFiling count
2026 Q14
2026 Q24
Approved exact aliases
PFIZER INC.
Included source names
PFIZER INC.
Excluded candidate records
12
Superseded records
0
Show 3 excluded source names
  • PFIZER
  • PFIZER, INC
  • PFIZER, INC.

Period: 2026 Q1 through 2026 Q2 Reviewed 2026-09-04

Full limitations

  • Source categories are presented separately and do not establish causation.
  • The page includes only exact client names in the reviewed alias allowlist.
  • Former-name evidence does not automatically merge subsidiaries, affiliates, committees, or separately named clients.
  • LDA data was retrieved for Gov Influence analysis; the Senate Office of Public Records cannot vouch for data or analyses after retrieval.
  • Gov Influence does not publish FEC individual-contributor records.
  • These reviewed records cover 2026 Q1 through 2026 Q2, not a complete account of the organization's activity.
  • Timing, identity, and subject overlap do not establish causation, motive, access, effectiveness, wrongdoing, or legal conclusions.
  • Names of individual lobbyists are not published on this profile.

Read the Methodology and Data Sources pages for the selection, evidence, and review rules used across the collection.